MA44728A - PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID - Google Patents
PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAIDInfo
- Publication number
- MA44728A MA44728A MA044728A MA44728A MA44728A MA 44728 A MA44728 A MA 44728A MA 044728 A MA044728 A MA 044728A MA 44728 A MA44728 A MA 44728A MA 44728 A MA44728 A MA 44728A
- Authority
- MA
- Morocco
- Prior art keywords
- betabloquant
- antihypertenseur
- nsaid
- pharmaceutical composition
- composition consisting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1653502A FR3050380B1 (en) | 2016-04-20 | 2016-04-20 | PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID. |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44728A true MA44728A (en) | 2019-02-27 |
Family
ID=56943614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA044728A MA44728A (en) | 2016-04-20 | 2017-04-19 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3445342A1 (en) |
KR (1) | KR102267965B1 (en) |
CN (1) | CN109069438A (en) |
BR (1) | BR112018070968A2 (en) |
EA (1) | EA201892354A1 (en) |
FR (1) | FR3050380B1 (en) |
GE (1) | GEP20217310B (en) |
MA (1) | MA44728A (en) |
PH (1) | PH12018502155A1 (en) |
RU (1) | RU2756320C2 (en) |
SG (2) | SG10202009894PA (en) |
TN (1) | TN2018000344A1 (en) |
UA (1) | UA125511C2 (en) |
WO (1) | WO2017182754A1 (en) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2645710C2 (en) | 1976-10-09 | 1985-06-27 | Merck Patent Gmbh, 6100 Darmstadt | Phenoxy-aminopropanols, process for their manufacture and pharmaceutical preparation |
FR2503155A2 (en) | 1980-10-02 | 1982-10-08 | Science Union & Cie | NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR |
FR2620709B1 (en) | 1987-09-17 | 1990-09-07 | Adir | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS |
FR2807431B1 (en) | 2000-04-06 | 2002-07-19 | Adir | NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
FR2827860B1 (en) | 2001-07-24 | 2004-12-10 | Servier Lab | NOVEL PROCESS FOR SYNTHESIS OF ACID DERIVATIVES (2S, 3AS, 7AS) -1 - [(S) -ALANYL] -OCTAHYDRO-1H-INDOLE-2-CARBOXYLINE AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL |
AR036187A1 (en) | 2001-07-24 | 2004-08-18 | Adir | A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ANALOG COMPOUNDS AND ITS SALTS, INTERMEDIARY COMPOUND 2,5-DIOXO-OXAZOLIDINE AND PROCESS TO PREPARE A INTERMEDIARY |
DE60220877T2 (en) | 2002-01-30 | 2008-04-10 | Les Laboratoires Servier | Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
FR2838648B1 (en) | 2002-04-18 | 2004-05-21 | Servier Lab | NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT |
EP1603558B1 (en) | 2003-02-28 | 2008-05-21 | Les Laboratoires Servier S.A. | Process for preparation of perindopril and salts thereof |
EP1403275B1 (en) | 2003-02-28 | 2005-10-19 | Les Laboratoires Servier | Process for the synthesis of perindopril and its pharmaceutically acceptable salts |
SI1321471T1 (en) | 2003-03-12 | 2005-08-31 | Servier Lab | |
DE60313391T2 (en) | 2003-06-30 | 2008-01-17 | Les Laboratoires Servier | Process for the synthesis of perindopril and its pharmaceutically acceptable salts |
DE60303101T2 (en) | 2003-06-30 | 2006-09-28 | Les Laboratoires Servier | Process for the synthesis of perindopril and its pharmaceutically acceptable salts |
CA2531279A1 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
ATE337332T1 (en) | 2003-07-31 | 2006-09-15 | Servier Lab | METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
ATE338058T1 (en) | 2003-07-31 | 2006-09-15 | Servier Lab | METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS |
DK1371659T3 (en) | 2003-08-29 | 2005-11-21 | Servier Lab | Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof |
DK1380591T3 (en) | 2003-08-29 | 2006-01-23 | Servier Lab | Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof |
EP1380590B1 (en) | 2003-08-29 | 2006-09-06 | Les Laboratoires Servier | Method for synthesis of perindopril and its pharmaceutically acceptable salts |
ES2282586T3 (en) | 2003-11-19 | 2007-10-16 | Les Laboratoires Servier | SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS. |
EP1422236B1 (en) | 2003-11-19 | 2007-02-14 | Les Laboratoires Servier | Method for synthesis of perindopril and its pharmaceutically acceptable salts |
ES2300555T3 (en) | 2003-12-10 | 2008-06-16 | Les Laboratoires Servier | SYNTHESIS PROCEDURE OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS. |
SI21800A (en) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | New procedure of synthesis of perindopril |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
FR2894825B1 (en) | 2005-12-21 | 2010-12-03 | Servier Lab | NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2897865B1 (en) | 2006-02-28 | 2008-04-18 | Servier Lab | BETA CRYSTALLINE SHAPE OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2897866B1 (en) | 2006-02-28 | 2008-04-18 | Servier Lab | ALPHA CRYSTALLINE FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
CN101024082A (en) * | 2007-04-06 | 2007-08-29 | 张士东 | Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof |
AU2009263737B2 (en) | 2008-06-24 | 2013-10-24 | Mylan Laboratories Ltd. | Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof |
HU230877B1 (en) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stable pharmaceutical combination |
NZ595127A (en) * | 2009-02-11 | 2013-08-30 | Cadila Pharmaceuticals Ltd | Stable pharmaceutical composition for atherosclerosis |
EP2424509A4 (en) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | Fixed dose drug combination formulations |
FR2961105B1 (en) | 2010-06-15 | 2013-02-08 | Servier Lab | USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY |
FR2985511B1 (en) | 2012-01-05 | 2014-01-03 | Servier Lab | CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
-
2016
- 2016-04-20 FR FR1653502A patent/FR3050380B1/en active Active
-
2017
- 2017-04-19 MA MA044728A patent/MA44728A/en unknown
- 2017-04-19 WO PCT/FR2017/050929 patent/WO2017182754A1/en active Application Filing
- 2017-04-19 BR BR112018070968A patent/BR112018070968A2/en not_active Application Discontinuation
- 2017-04-19 KR KR1020187033434A patent/KR102267965B1/en active IP Right Grant
- 2017-04-19 TN TNP/2018/000344A patent/TN2018000344A1/en unknown
- 2017-04-19 SG SG10202009894PA patent/SG10202009894PA/en unknown
- 2017-04-19 UA UAA201811111A patent/UA125511C2/en unknown
- 2017-04-19 GE GEAP201714923A patent/GEP20217310B/en unknown
- 2017-04-19 CN CN201780023915.6A patent/CN109069438A/en active Pending
- 2017-04-19 EP EP17722115.7A patent/EP3445342A1/en not_active Withdrawn
- 2017-04-19 RU RU2018140193A patent/RU2756320C2/en active
- 2017-04-19 SG SG11201808848SA patent/SG11201808848SA/en unknown
- 2017-04-19 EA EA201892354A patent/EA201892354A1/en unknown
-
2018
- 2018-10-05 PH PH12018502155A patent/PH12018502155A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180132911A (en) | 2018-12-12 |
WO2017182754A1 (en) | 2017-10-26 |
CN109069438A (en) | 2018-12-21 |
TN2018000344A1 (en) | 2020-06-15 |
EP3445342A1 (en) | 2019-02-27 |
SG11201808848SA (en) | 2018-11-29 |
RU2018140193A3 (en) | 2020-06-03 |
SG10202009894PA (en) | 2020-11-27 |
BR112018070968A2 (en) | 2019-01-29 |
GEP20217310B (en) | 2021-11-10 |
FR3050380A1 (en) | 2017-10-27 |
FR3050380B1 (en) | 2020-07-10 |
EA201892354A1 (en) | 2019-04-30 |
PH12018502155A1 (en) | 2019-07-15 |
RU2018140193A (en) | 2020-05-20 |
KR102267965B1 (en) | 2021-06-21 |
UA125511C2 (en) | 2022-04-13 |
RU2756320C2 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43709A (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF EMPAGLIFLOZIN AND ITS USES | |
MA46820A (en) | PHARMACEUTICAL COMPOSITION INCLUDING BI-SPECIFIC ANTIBODY CONSTRUCTIONS | |
MA49043A (en) | STABLE ANTIBODY FORMULATION | |
MA42971A (en) | ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PLD1 ANTIBODIES, AND METHODS OF USE THEREOF | |
MA46525A (en) | ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS | |
DK3331864T3 (en) | 1,3,4-Oxadiazole derivative compounds as histone deacetylase-6 inhibitor, and the pharmaceutical composition comprising these | |
EP3524603A4 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof | |
DK3328843T3 (en) | 1,3,4-OXADIAZOLESULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND THE PHARMACEUTICAL COMPOSITION | |
MA47499A (en) | ANTI-TAU BODIES AND THEIR METHODS OF USE | |
MA51747A (en) | LOW PH PHARMACEUTICAL ANTIBODY FORMULATION | |
MA44659A (en) | ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS | |
BR112017008666A2 (en) | anti-fgfr2 / 3 antibodies and methods of use | |
MA46109A (en) | HIGH CONCENTRATE, LOW VISCOSITY MASP-2 INHIBITOR ANTIBODY FORMULATIONS, KITS AND METHODS | |
MA44671A (en) | ASSOCIATIONS AND METHODS INCLUDING A CAPSIDE SET INHIBITOR | |
MA39248B1 (en) | Anti-jagged1 antibodies and methods of use thereof | |
MA54052A (en) | ANTIBODY FORMULATION | |
MA54139A (en) | ANTIBODY FORMULATION | |
FR3049465B1 (en) | PREVENTIVE AND CURATIVE PHARMACEUTICAL COMPOSITION BASED ON PEROXOMETALLATE | |
EP3810143A4 (en) | Nadph oxidase inhibitors, pharmaceutical composition comprising the same, and application thereof | |
MA47516A (en) | PHARMACEUTICAL COMPOSITION | |
BR112017001888A2 (en) | biological formulations for intravesical instillation | |
MA44286A (en) | PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN | |
CO2019000596A2 (en) | Combination of a bcl-2 inhibitor and an mcl1 inhibitor, uses and pharmaceutical compositions thereof | |
BR112017005993A2 (en) | innovative peptide derivatives and uses thereof | |
MA44728A (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETABLOQUANT, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSEUR OR AN NSAID |